Mölnlycke’s long-term net zero GHG emission reduction targets have been validated by the Science Based Targets initiative (SBTi).

This approval follows the prior validation of the medtech company’s near-term GHG emission reduction targets. 

Mölnlycke, which specializes in solutions for wound care and surgical procedures, committed to reaching net zero GHG emissions across the value chain by 2050. Specifically, the company has committed to reducing absolute Scope 1 and 2 GHG emissions by 90% by 2050 compared to the 2021 base year and seeks to lower Scope 3 GHG emissions by 97% per ton of sold product within the same timeframe.

“This validation represents a critical step in executing our strategy to drive decarbonization of healthcare. Reaching net zero demands measurable action, close collaboration, and innovation across the entire value chain. Mölnlycke is fully committed to working with its partners, suppliers, and customers to drive progress and deliver concrete outcomes,” says Caterina Camerani, VP Sustainability at Mölnlycke, in a statement.

The company is actively implementing initiatives to reach its near-term GHG emission reduction targets and achieved significant progress in 2024 by achieving 100% of renewable electricity at all manufacturing sites and its headquarters, as well as reaching a reduction of 40% in Scope 1 and 2 and 19% in Scope 3 GHG emissions against a 2021 base year.